We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock
LUMO

Delisted

LUMO was delisted on the 11th of December, 2024.

Back to rankings

130 hedge funds and large institutions have $196M invested in Lumos Pharma, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 43 increasing their positions, 26 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more call options, than puts

Call options by funds: $6.83M | Put options by funds: $3.24M

65% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 26

24% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 25

3% more funds holding

Funds holding: 126 → 130 (+4)

1% less capital invested

Capital invested by funds: $199M → $196M (-$2.52M)

Holders
130
Holders Change
+4
Holders Change %
+3.17%
% of All Funds
2.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
43
Reduced
26
Closed
25
Calls
$6.83M
Puts
$3.24M
Net Calls
+$3.59M
Net Calls Change
-$6.72M

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$18.3M
2
Millennium Management
Millennium Management
New York
+$9.64M
3
RG
Redmile Group
California
+$7.79M
4
ACA
Avoro Capital Advisors
New York
+$7.31M
5
BlackRock
BlackRock
New York
+$3.73M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$8.46M
2
CCI
Columbus Circle Investors
-$4.95M
3
MWNA
Marshall Wace North America
New York
-$3.88M
4
PP
PDT Partners
New York
-$3.56M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
TA
26
Teachers Advisors
New York
$1.08M +$544K +6,578 +80%
QI
27
QS Investors
New York
$1.08M -$62K -749 -5%
Hudson Bay Capital Management
28
Hudson Bay Capital Management
Connecticut
$1.01M +$1.15M +13,889 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$950K +$121K +1,467 +13%
SBH
30
Segall Bryant & Hamill
Illinois
$925K -$194K -2,342 -16%
Charles Schwab
31
Charles Schwab
California
$819K +$172K +2,079 +23%
BCM
32
Bridgeway Capital Management
Texas
$811K – – –
MCM
33
Moore Capital Management
New York
$811K +$459K +5,555 +100%
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
$810K +$541K +6,543 +144%
VF
35
Virtu Financial
New York
$798K +$904K +10,932 New
American Century Companies
36
American Century Companies
Missouri
$767K – – –
Citadel Advisors
37
Citadel Advisors
Florida
$656K +$545K +6,589 +275%
VRS
38
Virginia Retirement Systems
Virginia
$607K +$687K +8,311 New
CAM
39
ClariVest Asset Management
California
$604K +$684K +8,267 New
Morgan Stanley
40
Morgan Stanley
New York
$597K +$277K +3,344 +69%
SIM
41
Spark Investment Management
New York
$596K -$108K -1,311 -14%
Goldman Sachs
42
Goldman Sachs
New York
$524K +$145K +1,748 +32%
AllianceBernstein
43
AllianceBernstein
Tennessee
$497K – – –
TI
44
Trexquant Investment
Connecticut
$494K +$425K +5,143 +316%
Jacobs Levy Equity Management
45
Jacobs Levy Equity Management
New Jersey
$477K +$43.2K +522 +9%
Allianz Asset Management
46
Allianz Asset Management
Germany
$450K +$33.5K +405 +7%
LA
47
LexAurum Advisors
Kansas
$448K +$480K +5,801 New
NWM
48
Northwest Wealth Management
Iowa
$440K – – –
Dimensional Fund Advisors
49
Dimensional Fund Advisors
Texas
$436K -$223K -2,698 -31%
OAM
50
Oxford Asset Management
United Kingdom
$399K +$443K +5,361 New
1
2
3 4 5

LUMO Hedge Fund Activity: Q4 2017 in Review

130 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2017, worth a combined $196M — down 1.3% from $199M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new LUMO positions and 25 closed out — a net gain of 6 holders — while 43 added to existing stakes and 26 trimmed.

The largest buyer was Great Point Partners, opening a new position worth an estimated $18.3M. The largest seller was OrbiMed, exiting entirely with an estimated $8.46M sold.

  • 130 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2017, up from 126 in Q3 2017.
  • Funds reported $196M of Lumos Pharma, Inc. Common Stock stock for Q4 2017, down 1.3% quarter-over-quarter.
  • 31 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2017 and 25 closed out, a net change of +6 holders.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q4 2017 was Great Point Partners, an estimated $18.3M added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q4 2017 was OrbiMed, an estimated $8.46M sold.

Based on aggregated 13F filings for Q4 2017.